ArborMed is a biopharmaceutical company committed to the development and commercialization of therapeutics for diseases with high unmet medical needs and untapped market opportunities.
With operations in South Korea and US, Arbormed utilizes resources efficiently to enable "Fast to Market" development of the pipeline and US market entry.
Our Demand-Driven Development (D3) approach incorporates 3 strategic pillars to build a risk-balanced pipeline:
ARBORMED Co., Ltd.
|Parent Company||Innovative Drug Development|
|Location||Seoul, South Korea|
|Pipelines||3 innovative assets ARBM-101, Wilson’s disease therapy Ropivacaine ER Enbrel Biobetter|
|IPO KOSDAQ in Korea||2023~2024|
|Location||Seongnam, South Korea|
ARBORMED Pharmaceuticals Inc.
|Subsidiary(Wholly Owned)||US Medicine licensed distributor|
|Location||San Francisco, CA, USA|
|Pipelines||Acquired 7 complex generic products Oncology injections from Korea United Patch products from Icure Peptide injections from Penmix|
|FDA approval & launching||2023~2024|